Clinical trials: Cancer Refractory
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Sarcoma, Ewing, Neoplasm Metastasis
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment.
- Trial name
- NCT05440786
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 46 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Trial name
- NCT00125827
- Testing
- clofarabine (oral formulation)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with…
- Trial name
- NCT03218683
- Testing
- AZD5991, AZD5991 + Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide.
- Trial name
- OLYMPIA-5 (NCT06149286)
- Testing
- Odronextamab, Lenalidomide, Rituximab
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 580 people
- Sponsor
- Regeneron Pharmaceuticals
Tumor, Solid
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as…
- Trial name
- NCT05108623
- Testing
- agenT-797, Approved ICIs
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- MiNK Therapeutics
Acute Myeloid Leukemia
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML).
- Trial name
- NCT04155580
- Testing
- ASTX660, ASTX727
- Where
- 15 sites in United States
- Volunteers
- 68 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Prostate Cancer, mCRPC
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of…
- Trial name
- NCT05547061
- Testing
- Lu-177-DGUL, Ga-68-NGUL
- Where
- 4 sites in South Korea
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Cellbion Co., Ltd.
Multiple Myeloma
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as…
- Trial name
- NCT01421186
- Testing
- MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone
- Where
- 10 sites in Austria, Germany
- Volunteers
- 91 people
- Sponsor
- MorphoSys AG
Therapy, Prostatic Neoplasms
Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the safety of docetaxel administered every 3 weeks repeatedly for 11 and more cycles and in combination with daily prednisolone for metastatic hormone refractory prostate cancer.
- Trial name
- NCT00723086
- Testing
- docetaxel (XRP6976)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Sanofi
Gastric Cancer
Phase II Study of ABI-007 for Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of tri-weekly ABI-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease…
- Trial name
- NCT00661167
- Testing
- ABI-007
- Where
- 10 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Multiple Myeloma
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections…
- Trial name
- NCT05650632
- Testing
- Etentamig (ABBV-383)
- Where
- 46 sites in United States, Canada and 5 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Leukemia, Leukemia, Myeloid
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
There are limited options for treatment of relapse/refractory acute myeloid leukemia (AML). CD123 CAR-T cells may have an attractive and permanent effect on anti-tumor.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- Trial name
- NCT04265963
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Leukemia, Lymphoma
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
The purpose of this study is to determine whether Recombinant Human Arginase 1 (rhArg1)is safe and effective in the treatment of patients with Relapsed or Refractory Leukemia or Lymphoma.
- Trial name
- NCT01551628
- Testing
- Recombinant human arginase 1 Peg5000
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Bio-Cancer Treatment International Limited
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML)
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to…
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
- Trial name
- NCT06950034
- Testing
- STX-0712
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Solu Therapeutics, Inc
Non-small Cell Carcinoma, Adenocarcinoma of Lung
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
This 2-phase study will determine the safety of treating patients with non-small cell lung cancer with the genetically engineered HyperAcute-Lung cancer vaccine.
- Conditions
- Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma
- Trial name
- NCT00073398
- Testing
- Drug: Hyperacute Lung Cancer Cell Vaccine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- NewLink Genetics Corporation
Prostatic Neoplasms
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory…
- Trial name
- NCT00031187
- Testing
- SGN-15 (cBR96-doxorubicin immunoconjugate), Taxotere (docetaxel)
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- Seagen Inc.
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Advanced Cancer
Study of Oral Palifosfamide Tris in Solid Tumors
The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors
- Trial name
- NCT00607711
- Testing
- oral palifosfamide tris
- Sponsor
- Alaunos Therapeutics
Solid Tumor
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate…
- Trial name
- NCT06234098
- Testing
- AT-1965 Liposome Injection
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alyssum Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.